Tuesday, 17 Sep 2019

You are here

RABBIT Risk Scores are Higher in ICU-Admitted RA Patients

The German Rheumatoid Arthritis Biologics Registry (RABBIT) has developed an infectious risk calculator that can project a patient's risk of serious infection in the next 6 months based on several key factors - age, Prior DMARDs, prednisone dose, comorbidities and the biologic intended for use.  (This can be found at http://www.biologika-register.de

Others have used this formula to study whether RA patients admitted to an intensive care unit (ICU) for infection would have higher RABBIT risk scores compared to control RA patients.  They identified 74 RA patients with an infectious ICU admission and compared these to 74 frequency-matched control RA patients.

RABBIT risk scores were significantly higher in ICU RA patients (median 2.0; IQR 1.3-3.2) as compared to controls (1.3; IQR 0.8-2.0; p < 0.0001).  RA patients admitted to the ICU for infection were also more likely to be on DMARDs (82.4 vs 64.9%; p = 0.015), biologics (28.4 vs 14.9%; p = 0.012) and steroids (51.4 vs 31.1%; p = 0.012); suggesting those patients also had more active RA.

In a multivariable analysis conventional DMARD use was associated with lower (OR 0.38) and glucocorticoids with borderline higher odds of ICU admission (OR 2.05).

Chronic obstructive pulmonary disease (OR 2.89), chronic kidney disease (OR 16.08), and age (OR 2.67) were alson strongly associated with ICU admission.

Increasing RABBIT risk scores was associated with a strong trend towards higher odds of ICU admission for infection.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).